Menu
Home / Guides / Does Aetna cover Zepbound?
From Aetna’s own criteria and drug lists.
Does Aetna Cover Zepbound or Wegovy for Weight Loss?
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD (NPI 1144260043) · Updated
Only if your plan includes weight-loss drugs. Aetna’s 2027 Standard Plan drug guide lists Zepbound and Wegovy, but each employer decides whether its plan covers them, and Aetna’s criteria ask for a BMI of 30, or 27 with a related condition (35 on a stricter set; read Nov. 18, 2026). If your plan says no, compounded tirzepatide, which isn’t FDA-approved, is $115 a month at NexLife on the 12-month plan, or $129 month to month.
- Aetna’s criteria (September 2026): a BMI of 30, or 27 with a related condition, after 6 months in a weight program
- Aetna’s 2027 Standard Plan guide: lists Zepbound, Wegovy and Foundayo
- Medicare and Medicaid plans: different rules, set by Medicare and each state

$115/mo on a 12-month plan, all-inclusive, same price at every dose
Or $129/mo month to month
Self-pay, with no membership fee. A licensed provider decides if it’s right for you
About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication
See all 4 plans and what a year costs
| Plan | Per month | 12 months at this rate |
|---|---|---|
| 12-month Most savings | $115 | $1,380 |
| 6-month | $119 | $1,428 |
| 3-month | $125 | $1,500 |
| Month to month | $129 | $1,548 |
Month to month costs $168 more over 12 months than the 12-month plan. Plans renew until you cancel. Month to month is billed monthly. The 3-, 6- and 12-month plans are paid upfront at checkout: $375, $714 or $1,380.
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026)LegitScript-certified
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.
- Licensed U.S. providers
- LegitScript certified
- Free expedited shipping
- HSA, FSA, Affirm, Klarna, Afterpay
- 24/7 support, real people
- Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)
Compounded tirzepatide and semaglutide aren’t FDA-approved and aren’t Zepbound or Wegovy. A licensed provider prescribes them only when they offer a significant difference for you.
The short version
Does Aetna cover Zepbound or Wegovy? The answer at a glance
| Question | Answer |
|---|---|
| Does Aetna cover Zepbound for weight loss? | Only if your plan covers weight-loss drugs. Zepbound is on Aetna’s 2027 Standard Plan drug guide, but the guide says your plan design may not cover certain drugs or categories. Prior authorization is required. |
| Does Aetna cover Wegovy? | By the same rules. Wegovy and Wegovy HD are on that guide, and Aetna’s Wegovy criteria cover the shot and the pill, with prior authorization, if your plan covers weight-loss drugs. |
| What does Aetna ask for? | A BMI of 30, or 27 with a related condition, and at least 6 months in a weight management program before the drug (criteria revised September 2026). A stricter Aetna set asks for a BMI of 35 and doesn’t say which plans use it. |
| How long does approval last? | 8 months at first, or 6 for the Wegovy pill. Renewals last 12 months if you’ve lost at least 5% of your starting weight or kept that 5% off. |
| On Aetna Medicare or Medicaid? | Medicare generally doesn’t cover them for weight loss alone; CMS runs a $50 Bridge for people who qualify. Aetna Better Health follows each state’s Medicaid rules, which differ. |
| Paying yourself instead? | Compounded tirzepatide at NexLife: $115 a month on the 12-month plan or $129 month to month, at every dose. Not FDA-approved; NexLife doesn’t bill Aetna. |
From Aetna’s prior authorization criteria (revised September 2026), its Standard Plan drug guide for January 2027, Aetna Medicare’s Bridge page (updated October 15, 2026) and Aetna Better Health’s policy (effective November 17, 2026), all read Nov. 18, 2026. NexLife’s prices from our plan page.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- Zepbound and Wegovy are on Aetna’s 2027 Standard Plan drug guide, but your employer’s plan decides whether weight-loss drugs are covered (read Nov. 18, 2026).
- Aetna’s prior authorization asks for a BMI of 30, or 27 with a related condition, plus 6 months in a weight management program first (criteria revised September 2026).
- Approvals last 8 months at first, then 12 months if you’ve lost at least 5% of your starting weight or kept it off, under the same criteria.
- Zepbound was added to Aetna’s Standard Plan list on October 1, 2026, the day CVS Caremark made it a preferred option again.
- Medicare and Medicaid plans differ: Aetna Medicare points weight-loss use to CMS’s $50 Bridge, and Aetna Better Health follows each state’s Medicaid rules.
- Paying yourself? Compounded tirzepatide through NexLife, not FDA-approved, is $115 a month on the 12-month plan. NexLife doesn’t bill Aetna.
Who decides
Who decides whether your Aetna plan covers Zepbound or Wegovy?
Your employer or plan sponsor decides what your plan covers, and Aetna’s prior authorization rules apply on top. Aetna’s 2027 Standard Plan drug guide lists Zepbound, Wegovy, Wegovy HD and Foundayo, but the same guide says it isn’t an all-inclusive list and doesn’t guarantee coverage. So a drug on the list can still be outside your plan. What’s changing for every kind of plan:
“Your specific prescription benefit plan design may not cover certain medications, products or categories”
Your employer picks the plan design. Aetna’s Standard Plan exclusion list (October 2026) tells members, “Your prescription drug coverage is provided by your employer.” And Aetna’s September 28, 2026 letter to members of its federal Advanced Control Plan says a plan “may not cover certain drugs” for some conditions, weight loss among them, though OPM says federal plans will keep covering at least one weight-loss
Aetna and CVS Caremark are part of one company. CVS Health owns both (Healthcare Dive, May 1, 2025), and Aetna’s pharmacy documents carry its name. CVS said on May 28, 2026 that plan sponsors using Caremark’s template drug lists “retain discretion to customize coverage for their members.”
Which kind of Aetna plan do you have?
Check your member ID card and plan documents first, because the rules change with the plan type. Here’s what decides coverage for weight loss in each kind of Aetna plan.
| Your Aetna plan | For weight loss alone? | What decides |
|---|---|---|
| Through an employercommercial plan | Only if your plan covers weight-loss drugs | Your employer’s plan design, then Aetna’s prior authorization criteria (revised September 2026) |
| Aetna MedicareMedicare Advantage with drug coverage | Generally no; CMS’s $50 Bridge may help | Medicare’s rules. Part D may cover |
| Aetna Better HealthMedicaid and CHIP | Depends on your state | Your state’s Medicaid rules. Aetna’s policy for Florida, Illinois and Pennsylvania Kids excludes weight loss alone (effective November 17, 2026); Virginia allows it with strict BMI rules (state form revised April 16, 2026) |
| Aetna federal plansfor federal employees and retirees | At least one weight-loss | Your plan’s 2027 drug list, plus documented intensive behavioral therapy before and during treatment, which every federal carrier will require in 2027 (OPM) |
| An individual planHealthCare.gov or a state exchange | Not sold by Aetna | CVS said on May 1, 2025 that Aetna would stop selling ACA exchange plans in 2026 (Healthcare Dive). Compare other insurers’ drug lists before you enroll |
Swipe the table sideways to see every column.
What decides Aetna coverage of Zepbound and Wegovy for weight loss, by type of plan, from Aetna’s documents (read Nov. 18, 2026), NexLife’s state guides, OPM (read Nov. 15, 2026) and Healthcare Dive (May 1, 2025)
Prior authorization
What does Aetna require for prior authorization?
Aetna’s prior authorization for Zepbound or Wegovy checks three things: your starting BMI, any weight-related condition and at least 6 months in a weight management program before the drug, with chart notes required for the BMI and conditions. These are Aetna’s Zepbound and Wegovy criteria for plans that cover the drugs, revised in September 2026 and read Nov. 18, 2026.
| Who it’s for | Adults using the drug with a reduced-calorie diet and more physical activity. For Wegovy shots, also teens 12 to 17 with a BMI at or above the 95th percentile for age and sex. |
|---|---|
| Starting BMI | 30 or more, or 27 or more with at least one related condition |
| Conditions that count | High blood pressure, dyslipidemia, type 2 diabetes, obstructive sleep apnea, heart disease, MASH or MASLD, prediabetes, chronic kidney disease (stage 2 or higher), or knee or hip osteoarthritis |
| The program | At least 6 months in a comprehensive weight management program, with behavior change, a reduced-calorie diet, more activity and follow-up, before the drug starts |
| Proof | Chart notes showing your starting BMI and conditions |
| First approval | 8 months for Zepbound and Wegovy shots; 6 months for the Wegovy pill; 7 months for teens |
| Renewal | 12 months, after at least 3 months on a steady dose, if you’ve lost at least 5% of your starting weight or kept that 5% off |
| Fill limits | Zepbound: 4 pens or 1 KwikPen per 28 days. Wegovy shots: one 4-dose pack or pen per 28 days; the pill, 30 tablets per 30 days |
| Zepbound vials | Not under these criteria: Aetna says vials are covered under Lilly’s LillyDirect program |
Already taking Zepbound or Wegovy?
Aetna judges your BMI from when you started. If you move to Zepbound or Wegovy from another weight-loss drug, its criteria use your BMI and conditions from the start of any drug therapy. A renewal needs at least 3 months on a steady dose plus the 5% rule; a request that misses the 3 months is reviewed as a new start. Ask your prescriber to send your starting weight, today’s weight and the dates.
Does every Aetna plan use these numbers?
Not necessarily. Aetna also posts a stricter set for Zepbound, Wegovy, Foundayo and Saxenda that asks for a starting BMI of 35 or more, with no lower BMI for people with a related condition (policy 6450-C, page dated April 10, 2026). It doesn’t say which plans use it, so ask Aetna which criteria apply to your plan before your prescriber sends a request.
Your cost
What will Zepbound or Wegovy cost you with Aetna coverage?
Your share depends on your plan’s copay or coinsurance and your deductible, which Aetna’s drug guide doesn’t list. Aetna’s formulary notice for October 1, 2026 says costs “will depend on several things, like where you are with your deductible.” Sign in to your Aetna member site to price your own fill. Wegovy’s 2027 prices: Wegovy price in 2027.
- $25 as little as, for a Zepbound single-dose pen fill with Lilly’s card commercial coverage; current terms end December 31, 2026
- $675 Wegovy’s list price from January 1, 2027 down from $1,349.02, Novo Nordisk
- Oct. 1 Zepbound added to Aetna’s Standard Plan list Aetna notice, updates as of July 1, 2026
Savings cards work with employer coverage. If your Aetna plan covers Zepbound single-dose pens, Lilly’s savings card can bring a fill to as little as $25, saving up to $100 a month and $1,300 a year; its current terms end December 31, 2026 (checked Nov. 15, 2026). Novo’s Wegovy card works the same way, with savings up to $100 a month (terms read Nov. 15, 2026). Neither card works with Medicare, Medicaid or other government coverage.
Does Wegovy’s lower list price help?
It can if you pay coinsurance or haven’t met your deductible. Novo Nordisk says its cut to $675 on January 1, 2027 is meant for people whose costs are linked to list price, such as those with high-deductible plans or coinsurance. A flat copay doesn’t change unless your plan changes it.
Where do you see your own price?
On your Aetna member site. Aetna’s October 1, 2026 notice says members can sign in to “search for and estimate the cost of your drug(s).” Your plan documents list what you pay for preferred and non-preferred brand-name drugs.
Other uses
Does Aetna cover Zepbound for sleep apnea, or Wegovy for heart or liver disease?
It can. Aetna has separate criteria for these FDA-approved uses, revised in September 2026, but your plan’s drug list still decides whether the drug is covered. Aetna Medicare says Part D may cover them for sleep apnea or MASH, depending on the plan’s drug list. Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity. Wegovy is approved to lower the risk of heart attack, stroke and heart-related death in adults with heart disease and obesity or overweight and, as a shot, to treat MASH, a fatty liver disease, with moderate to advanced liver scarring but no cirrhosis (an accelerated approval).
| Use | What Aetna’s criteria ask | Source |
|---|---|---|
| Zepbound for sleep apneamoderate to severe OSA | An adult with obesity, a sleep study showing an apnea-hypopnea index (AHI) of at least 15 events an hour, and a starting BMI of 30 or more. 6 months at first, then 12 months if symptoms improve. | Aetna policy 6192-C, revised September 2026 |
| Wegovy for heart riskadults with heart disease | A past heart attack or stroke, symptomatic peripheral artery disease, or a past bypass, stent or angioplasty; a BMI of 27 or more; no type 2 diabetes (Aetna points those patients to Ozempic); and standard heart treatment, unless there’s a reason not to. 12 months. | Aetna policy 4774-C, revised September 2026 |
| Wegovy for MASHshots only | MASH without cirrhosis and with stage F2 to F3 fibrosis, confirmed by a scan, a blood test score or a past biopsy, and prescribed by or with a gastroenterologist or liver specialist. 12 months. | Aetna policy 4774-C |
| Aetna MedicarePart D | Part D may cover | Aetna Medicare, updated October 15, 2026 |
| Aetna Better HealthFlorida, Illinois, Pennsylvania Kids | Wegovy for heart risk (BMI 27 or more) or MASH, and Zepbound for sleep apnea (AHI 15 or more, BMI 30 or more). Weight loss alone is excluded. | Aetna Better Health policy, effective November 17, 2026 |
Swipe the table sideways to see every column.
Aetna’s criteria for Zepbound and Wegovy beyond weight management, from its commercial criteria (revised September 2026), Aetna Medicare (updated October 15, 2026) and Aetna Better Health (effective November 17, 2026), read Nov. 18, 2026. Your plan’s drug list decides whether the drug is covered.
Medicare’s Bridge is for weight loss only. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease can’t use CMS’s $50 Bridge, so their Part D plan’s drug list decides instead (Medicare.gov, read Nov. 15, 2026).
CVS Caremark
What does CVS Caremark’s formulary mean for Aetna members?
CVS Caremark’s drug lists matter to Aetna members because CVS Health owns both Caremark and Aetna. Caremark made Wegovy its preferred weight-loss drug over Zepbound on its standard formulary from July 1, 2025 (Healthcare Dive, May 1, 2025), then made Zepbound “an additional preferred option” again on October 1, 2026 (CVS Health, May 28, 2026). Aetna’s Standard Plan list added Zepbound the same day.
- July 1, 2025 Caremark prefers Wegovy over Zepbound standard formulary; Healthcare Dive, May 1, 2025
- Oct. 1, 2026 Zepbound back as an additional preferred option CVS Health, May 28, 2026
- Jan. 2027 Aetna’s Standard Plan guide lists Zepbound and Wegovy read Nov. 18, 2026
- Caremark’s change covers its most common commercial lists, for plan sponsors who choose to cover these drugs, CVS Health said on May 28, 2026.
- Lilly says Zepbound coverage is back on select CVS Caremark formularies, starting at $25 a month with its savings card (read Nov. 15, 2026).
- Caremark lifted its new-drug block on Foundayo, Lilly’s daily
GLP-1 pill, on June 1, 2026, where plans approve coverage; Aetna’s Standard Plan made Foundayo preferred on October 1, 2026.
Not every Aetna list matches. On Aetna’s Advanced Control Plan, a notice with updates as of April 22, 2025 listed Wegovy, Zepbound, Saxenda, Qsymia and orlistat as removed from July 1, 2025. Aetna’s 2027 Standard Plan guide lists Zepbound and Wegovy. Search your own plan’s current list by name, and if your pharmacy card names a company other than Aetna or CVS Caremark, ask that company.
Medicare and Medicaid
Do Aetna Medicare and Aetna Better Health plans cover Zepbound or Wegovy?
Medicare’s rules and each state’s Medicaid rules decide coverage in Aetna’s Medicare and Medicaid plans. Medicare generally doesn’t cover
The Medicare
Who qualifies: people with Part D and a BMI of 35, or 30 or 27 with listed conditions, when they start a
Savings cards don’t work with Medicare or Medicaid. Lilly’s and Novo’s cards exclude government coverage, Aetna Medicare and Aetna Better Health included.
Aetna Better Health depends on your state. In Florida, Illinois and Pennsylvania Kids, its policy says “weight loss only is an excluded benefit and will not be covered” (effective November 17, 2026); it covers Wegovy for heart risk or MASH and Zepbound for sleep apnea, with criteria. Virginia’s Medicaid plans, Aetna’s among them, cover Wegovy for weight loss only with a BMI over 40, or over 37 with a related condition (state form revised April 16, 2026; our Virginia guide, checked Nov. 6, 2026). Michigan’s, Aetna’s included, have approved it only for morbid obesity after other options fail since January 1, 2026 (our Michigan guide, checked Nov. 15, 2026).
More states may add coverage. State Medicaid programs can join CMS’s BALANCE model, which covers
Step by step
How do you find out what your Aetna plan covers, step by step?
Six checks take you from your member ID card to a backup plan if the answer is no.
- Find your plan type. Your member ID card and plan documents show whether you have an employer plan, Aetna Medicare, Aetna Better Health or a federal plan. Each follows different rules.
- Search your drug list. Sign in to your Aetna member site and search Zepbound or Wegovy by name. Note its tier and any prior authorization. If your pharmacy card names another company, ask that company.
- Ask whether weight-loss drugs are covered. Aetna’s 2027 drug guide says your plan design may not cover certain categories. Ask your benefits team, in writing, whether your plan covers weight-loss drugs in 2027.
- Gather the prior authorization records. Aetna’s criteria (revised September 2026) ask about your starting BMI, any related condition and at least 6 months in a weight management program, and require chart notes for the BMI and conditions.
- Price your share. Check your copay or coinsurance and your deductible. With employer coverage, Lilly’s Zepbound card can bring a single-dose pen fill to as little as $25 through December 31, 2026.
- If the answer is no, act on the reason. Appeal a medical denial, ask HR about a plan exclusion, or price paying yourself: Zepbound vials are $299 to $449 a month at LillyDirect, and compounded tirzepatide, not FDA-approved, is $126 to $599 a month in our GLP-1 price index (checked Nov. 15, 2026).
Six checks, from your ID card to a backup plan.
Appeals
How do you appeal an Aetna denial?
An appeal fits when Aetna says you don’t meet its criteria; when your plan doesn’t cover weight-loss drugs at all, ask HR instead. Filing costs nothing, and federal rules give your plan deadlines. Here’s how it works, and where Aetna Medicare differs.
Get the reason in writing
Your plan must tell you in writing why it said no; for a prior authorization request, that’s within 15 days (HealthCare.gov, read Nov. 1, 2026). The reason shows whether an appeal can help.
File within 180 days
Federal rules give you 180 days from the denial to file (HealthCare.gov, read Nov. 1, 2026). Use your plan’s appeal form, or write with your name, member ID and claim number. Ask your prescriber for a letter that covers your starting BMI, related conditions, your 6 months in a weight program and, for a renewal, your weight since you started.
Expect an answer in 30 days
For a drug you haven’t had yet, the plan must decide within 30 days. If it still says no, you have 4 months to ask for an external review, decided within 45 days, or 72 hours if it’s urgent (HealthCare.gov, read Nov. 1, 2026).
Drug not on your list? Ask for an exception
Aetna’s formulary letters say your doctor can request a medical exception when a drug’s status changes, or you can call the number on your member ID card. If it’s approved, you still pay your plan’s cost share (Aetna notices, 2025 and September 28, 2026).
On Aetna Medicare?
Aetna Medicare says it answers a Part D appeal within 7 days, or 72 hours if you ask for a faster decision (Aetna Medicare, read Nov. 18, 2026). The Bridge is CMS’s program and has no appeals process: your prescriber can send the request again with new information.
When an appeal won’t help. If your employer left weight-loss drugs out of the plan, there’s no medical decision to overturn. Ask HR whether that will change at your next open enrollment. More on denials and renewals: lost
2027
What changes for Aetna members in 2027?
Several dated changes meet at the turn of the year. Lilly’s Zepbound savings card terms end December 31, 2026, Wegovy’s list price falls to $675 on January 1, 2027, and Aetna’s 2027 Standard Plan guide lists Zepbound and Wegovy. Check your own plan’s 2027 drug list again after January 1, 2027.
Zepbound joins Aetna’s Standard Plan list and Foundayo moves to preferred, Aetna’s notice says. CVS Caremark makes Zepbound an additional preferred option the same day.
Medicare Open Enrollment for 2027 plans, Aetna Medicare included. Check each plan’s 2027 drug list.
The latest version of Aetna Better Health’s Wegovy and Zepbound policy takes effect in Florida, Illinois and Pennsylvania Kids (Florida had an earlier version from October 21, 2025).
Lilly’s Zepbound savings card terms end; Lilly hadn’t posted 2027 terms when NexLife checked on Nov. 15, 2026. Wegovy’s $199 starter price for new self-pay patients ends too.
Wegovy’s list price falls to $675, and Part D’s out-of-pocket cap rises to $2,400. On Aetna’s federal Advanced Control list, Saxenda moves to a non-preferred tier.
Medicare’s GLP-1 Bridge runs through this date, CMS says.
Shopping for an individual plan? CVS said on May 1, 2025 that Aetna would stop selling ACA exchange plans in 2026 (Healthcare Dive). HealthCare.gov’s 2027 open enrollment runs November 1, 2026 to January 15, 2027, or to December 15 for coverage that starts January 1, 2027.
Paying yourself
What will you pay if Aetna won’t cover it?
If Aetna won’t cover Zepbound or Wegovy, you can pay yourself at the makers’ self-pay prices (read November 1, 2026). Zepbound vials are $299 to $449 a month at LillyDirect; $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. Through NovoCare, the Wegovy pen is $349 and the Wegovy pill $149 to $299. Compounded tirzepatide, which isn’t FDA-approved, costs $126 to $599 a month, month to month and all in, with a median of $285 across the 25 programs that publish a month-to-month price (checked Nov. 15, 2026).
| Option | A month | Good to know |
|---|---|---|
| Zepbound vials at LillyDirect4 vials a month | $299 to $449 | $449 from 7.5 mg if you refill within 45 days; $499 to $699 if not. No end date listed. The KwikPen is the same price today, through a Lilly self-pay card whose terms end December 31, 2026 |
| Wegovy pen through NovoCare0.25 to 2.4 mg | $349 | $399 for Wegovy HD. New patients: $199 for each of their first two fills (through Dec. 31, 2026), with the prescription written and received by that date |
| Wegovy pill through NovoCare30 tablets | $149 to $299 | By dose |
| Compounded tirzepatideonline programs; not FDA-approved | $126 to $599 | Month to month, all in: median $285 across 25 programs, checked Nov. 15, 2026 |
| Compounded tirzepatide at NexLife | $115 or $129 | $115 a month on the 12-month plan (paid upfront: $1,380), or $129 month to month (billed monthly); the same at every dose |
Swipe the table sideways to see every column.
Self-pay prices from LillyDirect, Lilly’s savings-card terms and NovoCare’s terms, read November 1, 2026: the medication alone, with your prescriber’s visit extra. Compounded prices from our
NexLife Price Match Guarantee†. Already on compounded tirzepatide or semaglutide with another licensed provider, and paying less? We match your regular monthly price. How it works
The makers’ self-pay rules. Novo’s self-pay terms say you can’t bill your plan for these purchases or count them toward a deductible.
At NexLife, compounded tirzepatide is $115 a month on the 12-month plan, $119 (6-month), $125 (3-month) or $129 month to month. Compounded semaglutide is $95 a month on the 12-month plan, $99 (6-month), $105 (3-month) or $109 month to month. Both are the same price at every dose, with no membership fee. NexLife doesn’t bill Aetna or any other insurer.
How it’s billed: month to month is billed once a month. The 3-, 6- and 12-month plans are paid upfront, in full, at checkout: $375, $714 or $1,380 for tirzepatide, and $315, $594 or $1,140 for semaglutide. A longer plan starts only if you’re prescribed.
Ways to pay: NexLife takes HSA and FSA cards and provides a letter of medical necessity if your plan asks for one. Affirm, Klarna or Afterpay are offered at checkout; approval is theirs to give.
A licensed provider decides whether compounded tirzepatide or semaglutide is right for you, after reviewing your health history and the dose you take now. The labels pair these medicines with a reduced-calorie diet and more physical activity: here’s what to eat on a
Every program
What do online programs charge for compounded tirzepatide and semaglutide?
Compounded tirzepatide runs $126 to $599 a month and compounded semaglutide $87 to $399, month to month and all in, in our
| In our index | Compounded tirzepatide | Compounded semaglutide |
|---|---|---|
| Month-to-month range ($ a month, all in) | $126 to $599 | $87 to $399 |
| Median ($ a month) | $285 | $199 |
| Programs that publish a month-to-month price | 25 | 27 |
| Lowest month-to-month price | Mondae, $126 | Mondae, $87 |
| Same price at every dose | 14 of the 25 | 14 of the 27 |
| Programs in the index’s table | 44 | 44 |
NexLife Price Match Guarantee†. Already on compounded tirzepatide or semaglutide with another licensed provider, and paying less? We match your regular monthly price. How it works
How NexLife compares. NexLife, which publishes this guide, charges $129 month to month for compounded tirzepatide, $156 under that median, and $109 for semaglutide, $90 under it. It charges the same at every dose, as 14 of the 25 tirzepatide programs and 14 of the 27 semaglutide programs do.
Not every program shows a price. 18 of the 43 programs selling injectable compounded tirzepatide publish no month-to-month price, so the medians count only the ones that do.
All in means the medication plus any required membership or program fee. Every program, its price and its notes: our
In their words
What do Aetna, the FDA and the Zepbound label say?
Three short lines from primary sources: Aetna on Medicare’s Bridge, the label on sleep apnea and the FDA on compounded medicines.
Aetna Medicare members who want a
“Aetna Medicare does not approve requests for the Medicare GLP-1 Bridge program.”
Aetna, The Medicare GLP-1 Bridge program (updated October 15, 2026)
Aetna’s sleep apnea criteria follow the use the FDA approved for Zepbound:
“to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026
If Aetna won’t cover a
“Compounded drugs are not FDA-approved.”
U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers
Zepbound and Wegovy are the FDA-approved brand-name medicines. Compounded tirzepatide and semaglutide are made by a pharmacy, aren’t FDA-approved and aren’t reviewed by the FDA for safety, effectiveness or quality.
Vial math
How many units is your tirzepatide or semaglutide dose?
On a compounded vial, the units depend on its strength. Here are the label doses at example strengths, with the math to check your own.
Tirzepatide
| Dose | mL at 25 mg/mL | Units (U-100) | On the label |
|---|---|---|---|
| 2.5 mg | 0.1 mL | 10 units | Starting dose, for 4 weeks |
| 5 mg | 0.2 mL | 20 units | A maintenance dose |
| 7.5 mg | 0.3 mL | 30 units | A step up |
| 10 mg | 0.4 mL | 40 units | A maintenance dose |
| 12.5 mg | 0.5 mL | 50 units | A step up |
| 15 mg | 0.6 mL | 60 units | The maximum, and a maintenance dose |
The math: mL = dose ÷ strength (mg per mL), and units = mL × 100. At 25 mg/mL, 10 mg is 10 ÷ 25 = 0.4 mL, or 40 units.
Semaglutide
| Weeks | Weekly dose | At 2.5 mg/mL | At 5 mg/mL |
|---|---|---|---|
| 1 to 4 | 0.25 mg | 0.1 mL (10 units) | 0.05 mL (5 units) |
| 5 to 8 | 0.5 mg | 0.2 mL (20 units) | 0.1 mL (10 units) |
| 9 to 12 | 1 mg | 0.4 mL (40 units) | 0.2 mL (20 units) |
| 13 to 16 | 1.7 mg | 0.68 mL (68 units) | 0.34 mL (34 units) |
| 17 onward | 2.4 mg | 0.96 mL (96 units) | 0.48 mL (48 units) |
The math: mL = dose ÷ strength (mg per mL); units = mL × 100. At 2.5 mg/mL, 1 mg is 1 ÷ 2.5 = 0.4 mL, or 40 units. At 5 mg/mL, the same 1 mg is 0.2 mL, or 20 units.
25 mg per mL is an example only: it’s the strength of the 15 mg multi-dose vial on Zepbound’s label (15 mg per 0.6 mL). Read the strength on your own vial’s label; your provider sets your dose, in steps at least 4 weeks apart. Every step: the tirzepatide dosage chart. Or enter your own vial’s strength in the tirzepatide and semaglutide dosage calculator. Both strengths are examples only. The same dose is a different number of units at a different strength, so read the strength on your own vial’s label. Your prescription sets your dose and schedule, which may differ from these label steps. Every step: the semaglutide dosage chart.
What does NexLife cost?
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included.
GIP + 12-month plan $115/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan, $1,380 paid upfront; $129/mo month to month, billed monthly.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication

12-month plan $95/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
TrustScore 4.8 out of 5 on Trustpilot 407 reviews as of Nov. 15, 2026 · Read them all ↗
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
Loved by our members
Real stories from NexLife members about their care and service.
A selection of 5-star reviews from Trustpilot, quoted in full as written. Results vary from person to person, and weight loss isn’t guaranteed.
★★★★★TrustScore 4.8 out of 5 on Trustpilot407 reviews as of Nov. 15, 2026 · Read them all ↗
★★★★★Read on Trustpilot ↗
“That’s a real site with good prices and plans!”
Estefany L.
★★★★★Read on Trustpilot ↗
“Affordable, quick and easy. They could not have made it a smoother less stressful experience.”
Andisheh K.
★★★★★Read on Trustpilot ↗
“Great communication. Easy to work with. They work to set you up for success.”
Anthony C.
★★★★★Read on Trustpilot ↗
“Fast delivery and easy to get a hold of when needing to talk with someone!”
Browneyes
★★★★★Read on Trustpilot ↗
“So happy with NexLife. Communication has been great, I’m recommending them to all my friends.”
April
★★★★★Read on Trustpilot ↗
“Excellent visit. Dr. Kennah was very knowledgeable and helpful and answered all my questions.”
Ethan B.
★★★★★Read on Trustpilot ↗
“Fast service great communication!! Willing to work with you!”
Bon
★★★★★Read on Trustpilot ↗
“Great service and excellent communication!”
Gabrielle D.
★★★★★Read on Trustpilot ↗
“Easy and pricing not bad! Customer service was helpful in answering my questions.”
Lyndy T.
★★★★★Read on Trustpilot ↗
“Good experience, great team”
Mai S.
★★★★★Read on Trustpilot ↗
“Great communciation and was fast and reliable”
Kiki
★★★★★Read on Trustpilot ↗
“Very happy so far”
Tammy E.
Names are shortened for privacy. Reviews are members’ opinions, not medical advice.
Does Aetna cover Zepbound? Your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
Does Aetna cover Zepbound for weight loss?
Only if your plan covers weight-loss drugs and you meet Aetna’s criteria. Zepbound is on Aetna’s 2027 Standard Plan drug guide, but the guide says your plan design may not cover certain categories. With coverage, Aetna’s Zepbound criteria ask for a BMI of 30, or 27 with a related condition, and 6 months in a weight management program first (revised September 2026, read Nov. 18, 2026). A stricter Aetna set asks for 35 and doesn’t say which plans use it.
Does Aetna cover Wegovy for weight loss?
The same rules apply. Wegovy and Wegovy HD are on Aetna’s 2027 Standard Plan drug guide, and Aetna’s Wegovy criteria, which cover the shot and the pill, ask for a BMI of 30, or 27 with a related condition, plus 6 months in a weight management program (revised September 2026). Your employer still decides whether the plan covers weight-loss drugs. Aetna’s criteria also include teens 12 to 17 with obesity, for the Wegovy shot only.
Does Aetna cover GLP-1 medications?
For type 2 diabetes, Aetna’s 2027 Standard Plan guide lists Ozempic, Rybelsus and Trulicity, plus Mounjaro, which acts on GIP and GLP-1. For weight loss, it lists Zepbound, Wegovy and Foundayo, but coverage depends on your plan and Aetna’s prior authorization. Aetna Medicare generally doesn’t cover them for weight loss alone, and Aetna Better Health follows each state’s Medicaid rules (read Nov. 18, 2026).
What BMI does Aetna require for Zepbound or Wegovy?
A starting BMI of 30 or more, or 27 or more with at least one related condition, such as high blood pressure, type 2 diabetes, sleep apnea or prediabetes, under Aetna’s criteria revised September 2026. Aetna also posts a stricter set that asks for a BMI of 35 or more (policy 6450-C) and doesn’t say which plans use it; ask Aetna which one applies to your plan. The BMI that counts is the one from when you started drug therapy.
How long does an Aetna approval last?
8 months for a first approval of Zepbound or Wegovy shots, or 6 months for the Wegovy pill, under Aetna’s criteria revised September 2026. Renewals last 12 months once you’ve had at least 3 months on a steady dose and lost at least 5% of your starting weight, or kept that first 5% off. For sleep apnea, a first Zepbound approval lasts 6 months.
Does Aetna cover Zepbound for sleep apnea?
If your plan covers Zepbound, Aetna’s criteria (revised September 2026) allow it for adults with obesity and moderate to severe obstructive sleep apnea: a sleep study showing an AHI of at least 15 events an hour, and a starting BMI of 30 or more. A first approval lasts 6 months, then 12 months if symptoms improve. Aetna Medicare plans may cover it too, depending on the plan’s drug list.
Is Zepbound back on Aetna’s formulary?
On the Aetna Standard Plan, yes: Aetna’s notice lists Zepbound among products added on October 1, 2026, and its 2027 drug guide lists it. CVS Caremark made Zepbound an additional preferred option on its most common commercial lists the same day. Employers can still customize their lists, so search your own plan’s list by name.
Does Aetna Medicare cover Zepbound or Wegovy for weight loss?
Not through Part D: Medicare generally doesn’t cover drugs for weight loss alone, CMS says. If you qualify, Medicare’s GLP-1 Bridge, run by CMS, covers Wegovy, Foundayo or the Zepbound KwikPen for $50 a month through December 31, 2027. Aetna Medicare says it doesn’t approve Bridge requests; your prescriber sends them to CMS. Details: Medicare and GLP-1s.
Does Aetna Better Health cover Wegovy or Zepbound?
It depends on your state. In Florida, Illinois and Pennsylvania Kids, Aetna Better Health’s policy, effective November 17, 2026, says weight loss only is an excluded benefit; it covers Wegovy for heart risk or MASH and Zepbound for sleep apnea, with criteria. Virginia’s Medicaid plans, Aetna’s among them, cover Wegovy for weight loss only with a BMI over 40, or over 37 with a related condition (state form revised April 16, 2026). Ask your plan in writing.
Can I use a Zepbound or Wegovy savings card with Aetna?
With employer or other commercial Aetna coverage that covers the drug, yes. Lilly’s card can bring a Zepbound single-dose pen fill to as little as $25, saving up to $100 a month, until its terms end December 31, 2026; Novo’s Wegovy card offers savings up to $100 a month (both checked Nov. 15, 2026). Neither works with Aetna Medicare, Aetna Better Health or other government coverage.
How do I appeal an Aetna denial for Zepbound or Wegovy?
Get the reason in writing, then file within 180 days with a letter from your prescriber covering your starting BMI, conditions and weight program. For a drug you haven’t had yet, the plan must decide within 30 days, and you can then ask for an external review within 4 months (HealthCare.gov, read Nov. 1, 2026). If your employer left weight-loss drugs out, ask HR instead.
Does NexLife take Aetna insurance?
No. NexLife is self-pay and doesn’t bill Aetna or any other insurer: compounded tirzepatide, which isn’t FDA-approved, is $115 a month on the 12-month plan, or $129 month to month, at every dose. You can pay with an HSA or FSA card, and NexLife provides a letter of medical necessity if your plan asks for one.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, constipation and stomach pain.
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who wrote and medically reviewed this page?
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Aetna’s criteria, drug lists, and Medicare and Medicaid pages read Nov. 18, 2026; self-pay prices checked Nov. 1, 2026; savings cards and compounded prices checked Nov. 15, 2026.
- How we checked. Aetna facts come only from Aetna’s own documents, read Nov. 18, 2026: its prior authorization criteria for Zepbound and Wegovy, its Standard Plan formulary notices and 2027 drug guide, its Medicare Bridge and appeals pages, and Aetna Better Health’s policy. CVS Caremark’s changes come from CVS Health’s May 28, 2026 release, and the approved uses from the FDA-approved prescribing information. Federal rules come from Medicare.gov, CMS, OPM and HealthCare.gov, and state Medicaid rules from NexLife’s state guides. Self-pay prices are the makers’ own. Coverage depends on your plan, so check your own before you rely on any of this. We don’t suggest NexLife meets any plan’s weight management program requirement.
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
- How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves
Plan won’t cover your GLP-1 in 2027? Here’s one option.
A 3-minute online check, then a licensed provider decides if compounded tirzepatide is right for you. It’s $115 a month on the 12-month plan, or $129 month to month, at every dose.
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, following your state’s rules. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Aetna: Zepbound prior authorization criteria, policy 6192-C (revised September 2026). Read Nov. 18, 2026.
- Aetna: Wegovy prior authorization criteria, policy 4774-C (revised September 2026). Read Nov. 18, 2026.
- Aetna: Weight Loss (BMI 35) criteria, policy 6450-C (page dated April 10, 2026). Read Nov. 18, 2026.
- Aetna: Formulary updates for the Aetna Standard Plan, effective October 1, 2026 (PDF). Read Nov. 18, 2026.
- Aetna: 2026 Formulary Exclusions Drug List, Aetna Standard Plan (October 2026; PDF). Read Nov. 18, 2026.
- Aetna: 2027 Aetna Standard Plan Pharmacy Drug Guide (January 2027; PDF). Read Nov. 18, 2026.
- Aetna: Advanced Control Plan drug coverage changes starting July 1, 2025 (updates as of April 22, 2025; PDF). Read Nov. 18, 2026.
- Aetna: Advanced Control Plan for federal employees, changes starting January 1, 2027 (letter dated September 28, 2026; PDF). Read Nov. 18, 2026.
- Aetna Medicare: The Medicare GLP-1 Bridge program (updated October 15, 2026). Read Nov. 18, 2026.
- Aetna Medicare: Coverage decisions, appeals and grievances. Read Nov. 18, 2026.
- Aetna Better Health: Wegovy cardiovascular and Zepbound OSA coverage policy (effective November 17, 2026; PDF). Read Nov. 18, 2026.
- CVS Health: CVS Caremark delivers affordability and access to GLP-1 weight management medications (May 28, 2026). Read Nov. 18, 2026.
- Healthcare Dive: CVS plans to exit ACA individual exchanges, strikes Wegovy deal with Novo Nordisk (May 1, 2025). Read Nov. 18, 2026.
- Eli Lilly: Zepbound (tirzepatide) prescribing information, revised August 2026. Read Nov. 18, 2026.
- Novo Nordisk: Wegovy (semaglutide) prescribing information, revised June 2026. Read Nov. 18, 2026.
- Medicare.gov: Weight loss drugs (the Medicare GLP-1 Bridge). Read Nov. 15, 2026.
- CMS: Medicare GLP-1 Bridge (page modified July 13, 2026). Read Nov. 15, 2026.
- CMS fact sheet: What’s the Medicare Prescription Payment Plan? (September 2026), the $2,400 out-of-pocket cap in 2027. Read Nov. 15, 2026.
- CMS: BALANCE Model (page modified September 29, 2026). Read Nov. 15, 2026.
- Medicare.gov: Open Enrollment. Read November 1, 2026.
- OPM: Federal Benefits Open Season Highlights, 2027 plan year. Read Nov. 15, 2026.
- HealthCare.gov: Internal appeals. Read November 1, 2026.
- HealthCare.gov: External review. Read November 1, 2026.
- HealthCare.gov: When can you get health insurance? (dates and deadlines). Read Nov. 15, 2026.
- Eli Lilly: Zepbound savings and insurance options (savings card terms). Read Nov. 15, 2026.
- LillyDirect: Zepbound self-pay prices. Checked November 15, 2026.
- NovoCare: Wegovy savings offer and self-pay terms. Read Nov. 15, 2026.
- NovoCare Pharmacy: terms and self-pay prices. Read Nov. 15, 2026.
- Novo Nordisk: US list price reduction for Wegovy, Ozempic and Rybelsus (February 24, 2026). Read Nov. 15, 2026.
- FDA: Compounding and the FDA, questions and answers. Read Nov. 15, 2026.
- NexLife:
GLP-1 price index. Compounded prices checked Nov. 15, 2026. - NexLife: pricing, every plan.